secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-107014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback
-------------------------------------------------------------------------

- Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
- Net income $89.9M ($1.30 basic EPS) vs $1.2M ($0.02) in Q3 2024; driven by $62.3M fair-value gains on equity investments.
- Income from operations $34.6M, down 20% primarily due to non-recurring R&D expense.
- Board authorized $125M share repurchase program; $192.5M of convertible notes converted into 11.1M shares in August.
- ZEVTERA U.S. launch in July; zoliflodacin PDUFA Dec 15, 2025; investments: Armata $15M, Lyndra $10.2M, Beacon Biosignals $17.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/0001104659-25-107014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925107014/tm2530226d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer